This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next 12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI in the context of circulating SARS-CoV-2.

中文翻译：

---

COVID-19 时期的 HIV 治愈研究 - 抗逆转录病毒治疗中断试验：讨论文件

本讨论文件讨论了 HIV 治愈研究的安全性，特别是那些涉及停止抗逆转录病毒治疗的研究，即 SARS-CoV-2 大流行背景下的分析治疗中断 (ATI)。 ClinicalTrials.gov 上列出的 30 多项研究包括 ATI 和许多其他研究计划在未来 12 个月内开始，但大多数由于 COVID-19 大流行而停止。我们认为在重新开放艾滋病毒治疗临床试验之前需要考虑伦理、风险和实际考虑因素，并注意到在 SARS-CoV-2 流行的背景下 ATI 的具体风险。